35 results
424B3
PRTG
Portage Biotech Inc.
27 Aug 24
Prospectus supplement
6:11am
. The Merck collaboration terminated in December 2023.
Preliminary Phase 1 data from the IMP-MEL PORT-2 clinical trial, presented at the Society
6-K
EX-99.2
PRTG
Portage Biotech Inc.
27 Aug 24
Current report (foreign)
6:05am
terminated in December 2023.
Preliminary Phase 1 data from the IMP-MEL PORT-2 clinical trial, presented at the Society for Immunotherapy of Cancer
6-K
EX-99.1
PRTG
Portage Biotech Inc.
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
update at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and presenting final data from the Phase 1a portion of ADPORT-601 (PORT-6 … ) at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting later this year,” said Dr. Ian Walters, Chief Executive Officer and Chairman
424B3
PRTG
Portage Biotech Inc.
28 Feb 24
Prospectus supplement
5:19pm
trial, presented at the Society for Immunotherapy of Cancer in November 2023, suggests PORT-2 was well tolerated when administered as a monotherapy
6-K
EX-99.2
s0k9ubvvcdrwxfydb
28 Feb 24
Current report (foreign)
5:17pm
424B3
prw3wbp
28 Nov 23
Prospectus supplement
4:03pm
6-K
EX-99.1
0v5o4lbqk7yw6wdw
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
6-K
EX-99.2
v04unhir 5tphd
28 Nov 23
Current report (foreign)
4:01pm
6-K
EX-99.1
dl59544
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
0rz4sh z3cksifhe024
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.2
yu7eh
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.1
sk74n
9 Nov 22
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
4:01pm
6-K
EX-99.2
u3vc rf946g
29 Aug 22
Current report (foreign)
4:00pm
6-K
EX-99.1
v6i0p
1 Aug 22
Current report (foreign)
4:48pm
6-K
EX-99.2
ltbze8thpsp27b1r5tuh
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
01i6nfu swir5f9
23 Nov 21
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.1
okfxdygdzbz71a0i3q
30 Aug 21
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
8:00am